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Abstract
We describe a child with dyserythropoietic anemia; thrombocytosis; functional platelet defect and 
megakaryocyte dysplasia. We show that (i) this constellation of hematopoietic abnormalities was 
due to a germline mutation within the 5′UTR of GATA1; (ii) the mutation impaired a 5′UTR 
GATA1 splicing site, promoting production of the shortened GATA1s isoform lacking the N-
terminus; (iii) expression of the GATA1 N-terminus is restricted to erythroblasts and 
megakaryocytes in normal marrow, consistent with the patient’s abnormal erythropoiesis and 
megakaryopoiesis. Our findings provide insights into the clinically relevant in vivo function of the 
N-terminal domain of GATA1 in human hematopoiesis.
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Germline mutations within the X-linked transcription factor GATA1 occur in a spectrum of 
childhood blood disorders (reviewed in [1]). Alternative splicing produces two GATA1 
isoforms [2]: full-length GATA1 (flGATA1) and shortened GATA1 (GATA1s), which lacks 
the N-terminal domain.
Rare defects known as “GATA1s mutations” [3] reduce synthesis of full-length GATA1 
while GATA1s is still produced. Acquired GATA1s mutations drive transient 
myeloproliferative disorder and AML in Down syndrome patients (reviewed in [4–6]). 
Germline GATA1s mutations in individuals without trisomy 21 have been associated with 
Diamond-Blackfan anemia (DBA) [7,8], a syndrome of RBC aplasia and otherwise normal 
hematopoiesis [9]. DBA-associated ribosomopathy impairs GATA1 synthesis [10], perhaps 
because the complex structure of the GATA1 5′UTR demands error-free ribosomes for 
efficient translation. Thus, ribosomopathy has been mechanistically linked to GATA1 and 
erythropoiesis failure in DBA. However, thrombocytopenia with structural platelet 
abnormalities and dyserythropoiesis [11] as well as childhood myelodysplastic syndrome 
(MDS) [12] were reported in other GATA1s families. Since GATA1s patients are rare and 
clinically heterogeneous, the clinical impact of inherited GATA1s mutations on human 
hematopoiesis remains to be fully elucidated.
Results
We describe a child with dyserythropoietic anemia, megakaryocyte dysplasia and platelet 
malfunction due to a disease-causing mutation within the 5′UTR of GATA1. We explored 
the impact of this novel mutation on the expression of GATA1 splice variants in human bone 
marrow. Our findings support the role for the N-terminus of GATA1 in in vivo 
megakaryocyte function and erythropoiesis.
A 4-year old male developed fatigue and pallor secondary to anemia (hemoglobin: 4.4 g/dL). 
His growth and development were normal with no congenital malformations. His past blood 
counts revealed progressive macrocytic anemia with reticulocytopenia and persistent fetal 
hemoglobin first noted at 3 months of age, as well as chronic thrombocytosis (platelets:
387-947,000/mm3) and occasional neutropenia with no frequent infections (lowest absolute 
neutrophil count:495/mm3) (Figure 1A). The folate and vitamin B12 levels were normal. 
Normal DEB chromosome-breakage test and lymphocyte telomere length excluded Fanconi 
anemia and dyskeratosis congenita, respectively.
DBA was initially suspected due to progressive macrocytic anemia beginning in infancy [9]. 
However, the patient’s bone marrow analysis revealed not only paucity of RBC precursors 
(Figure 1B–C) and dyserythropoiesis (Supplementary Figure 1), but also prominent 
megakaryocytosis (Figure 1B–C) with megakaryocyte dysplasia (Figure 1B; Supplementary 
Figure 2), which is not seen in classic DBA [9]. Accordingly, sequencing of the patient’s 
nine DBA-associated ribosome genes (RPL11, RPL35a, RPL5, RPS10, RPS17, RPS19, 
RPS24, RPS26, and RPS7) and deletion-duplication analysis of RPS19, RPL5, RPL11, 
RPL35A, RPS17 and RPS26 produced normal results. Normal cytogenetics, MDS-FISH and 
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blast count excluded MDS. Thus, we asked whether his anemia mimicking DBA [7,8] but 
associated with megakaryocyte dysplasia [11] reflected a germline GATA1 defect. Indeed, 
Sanger sequencing revealed a novel mutation within the 5′UTR of GATA1 (c.-21A>G or 
c.-19-2A>G) at position 48,791,089 on the X-chromosome (GRCh38.p2 primary assembly), 
which affects the absolutely conserved A in the -2 position of the splice acceptor site (Figure 
1D). Consistent with an X-linked recessive inheritance, mother was an asymptomatic carrier, 
and all healthy male siblings had wild-type GATA1 (Figure 1D).
We hypothesized the GATA1c-.21A>G transcript splicing is abnormal as our in silico analysis 
[13] suggested disruption of a 5′UTR consensus splice site. Accordingly, the 
GATA1c-.21A>G mutation decreased in vivo flGATA1 expression (Figure 1E–F), which is 
consistent with the GATA1s phenotype [7,8,11,12]. The patient’s anemia improved on 
corticosteroids similar to other GATA1s individuals [7,8,12]. Thus, the GATA1c.-21A>G 
mutation produced the GATA1s phenotype through destruction of a splice site within the 
5′UTR of GATA1 (Figure 1G).
Past clinical reports have generated conflicting in vivo data regarding the impact of inherited 
GATA1s mutations on megakaryopoiesis in non-Down syndrome patients [7,8,11]. However, 
accumulation of dysplastic megakaryocytes in the GATA1c.-21A>G marrow with peripheral 
thrombocytosis strongly suggests that flGATA1 regulates human megakaryocyte 
proliferation and function in vivo in individuals without trisomy 21. Moreover, the 
GATA1c.-21A>G platelets displayed subclinical aggregation deficiencies (Supplementary 
Figure 3), further implicating flGATA1 in physiological megakaryopoiesis. Thus, we 
methodically examined GATA1 splicing in human marrow, hypothesizing that flGATA1 
expression correlates with the role of flGATA1 in distinct lineages. To that end, we 
developed an immunohistochemistry assay specific for the GATA1 N-terminus (Figure 2A). 
Full-length GATA1 was absent from the GATA1c.-21A>G marrow, confirming that the 
mutation confers GATA1s phenotype (Figure 2B–C). Double-immunohistochemistry 
detected flGATA1 in healthy megakaryocytes and erythroblasts but not in other 
hematopoietic lineages (Figure 2C), consistent with the observation that loss of flGATA1 
disrupted RBC and platelet production in our patient (Figure 1).
Discussion
GATA1 orchestrates the production of RBCs and platelets [14–16]. Alternative splicing 
provides an incompletely understood pathway to fine-tune this transcription factor’s activity 
during hematopoiesis. Full-length GATA1 differs from the short isoform (GATA1s) by the 
presence of the 83 amino acid-long N-terminus, which activates GATA1-driven 
erythropoiesis [2,17] and recruits flGATA1 to a subset of megakaryocyte and erythroblast 
genes [3]. Thus, GATA1 isoforms control partially overlapping but not identical 
transcriptional modules of erythroblast and megakaryocyte maturation.
Acquired GATA1s mutations are key drivers of transient myeloproliferation and AML in 
Down syndrome [4–6]. Inherited GATA1s mutations that decrease production of flGATA1 
through disrupting exon 2 splice sites [7,8,11] or the initiation codon [12] have been 
reported in rare non-Down syndrome patients (Figure 2). GATA1s patients uniformly 
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develop hyporegenerative anemia, confirming that the N-terminus of GATA1 is 
indispensable for erythropoiesis. However, since the reported clinical symptoms in GATA1s 
individuals range from DBA [7,8] to erythroblast and megakaryocyte dysplasia [11] and 
DBA progressing to MDS [12], the role of flGATA1 in other hematopoietic cell lines needs 
clarification.
Striking accumulation of dysplastic megakaryocytes in the GATA1c.-21A>G patient’s marrow 
(Figure 1) suggests that loss of flGATA1 unleashes megakaryocyte proliferation in vivo, 
possibly due to de-repression of the E2F cell-cycle regulator [18]. In further support of this 
notion, independent ex vivo studies showed that hematopoiesis in GATA1s iPS cells is 
skewed towards generation of abnormal megakaryocytes at the cost of erythropoiesis [3]. 
Indeed, expression of the GATA1 N-terminus is restricted to erythroblasts and 
megakaryocytes (Figure 2), supporting a physiological role of flGATA1 in these 
hematopoietic lineages. This assay may provide a future screening tool for GATA1s 
phenotype. Intriguingly, both thrombocytopenia [11] and thrombocytosis (this work) occur 
in GATA1s individuals, including GATA1s patients diagnosed with DBA [8]. A systematic 
evaluation of megakaryopoiesis in additional GATA1s patients will determine whether 
megakaryocyte dysplasia is universally seen in GATA1s individuals. Potential genotype-
phenotype correlations will remain unknown until more GATA1s patients are identified, 
especially since the same GATA1c.220G>C mutation caused DBA-like phenotype in one 
family [8] and multilineage dysplasia in another [11].
The GATA1c.-21A>G platelets are defective (Supplementary Figure 3). This is in agreement 
with ultrastructural platelet abnormalities described in GATA1c.220G>C family [11], likely 
secondary to disrupted cytoskeletal remodeling in flGATA1-deficient megakaryocytes [19]. 
Future studies will determine whether GATA1s patients develop clinically significant 
bleeding later in life.
Prominent megakaryocyte abnormalities (this work; [11]) may provide subtle clinical clues 
to differentiate GATA1s mutations from “classical” DBA caused by ribosomopathy, which is 
defined as pure red blood cell aplasia [9]. GATA1 sequencing should be considered in males 
with congenital multi-lineage dysplasia and/or DBA-like clinical presentation. Interestingly, 
MDS-associated spliceosome mutations globally alter expression of multiple hematopoietic 
regulators, including GATA1 [20]. Given the potential risk of MDS in GATA1s patients [12], 
hematopoiesis should be closely monitored in individuals with inborn GATA1s mutations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CD Cluster of differentiation
DEB Diepoxybutane
DBA Diamond-Blackfan anemia
FISH Fluorescent in situ hybridization
flGATA1 Full-length GATA1
GATA1 Globin transcription factor 1
GATA1s Shortened GATA1
iPS cells Induced pluripotent stem cells
IRB Institutional Review Board
MDS Myelodysplastic syndrome
NIH National Institutes of Health
RBC Red blood cell(s)
RNA Ribonucleic acid
RPL Ribosomal protein L
RPS Ribosomal protein S
RT-PCR Reverse transcription-polymerase chain reaction
5′UTR 5′ untranslated region
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Figure 1. Hypoplastic anemia, megakaryocyte dysplasia and thrombocytosis due to mutation 
within the 5′UTR of GATA1
(A) Chronic anemia and thrombocytosis over the course of 5 years. (B) Decreased 
erythropoiesis and megakaryocyte dysplasia seen on bone marrow aspirate. (C) 
Immunohistochemistry with CD71 (erythroblast marker) and CD61 (megakaryocyte marker) 
reveals decreased erythropoiesis and accumulation of megakaryocytes in the patient’s bone 
marrow compared to a healthy individual. Right panel shows dysplastic megakaryocytes 
(black arrows) in the patient’s marrow (Wright-Giemsa stain). (D) GATA1 sequencing 
reveals a novel mutation in the affected child. RT-PCR and Western blotting demonstrate 
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decreased full-length GATA1 transcript (E) and protein (F) in the patient. (G) Schematic 
representation of GATA1 alternative splicing (only first three exons are shown for 
simplicity). The GATA1c-.21A>G mutation produces GATA1s phenotype by disrupting full-
length GATA1 splicing.
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Figure 2. Full-length GATA1 expression is restricted to erythrocyte and megakaryocyte 
precursors during hematopoiesis
(A) Antibodies used for immunohistochemistry. Antibody against the N-terminus of GATA1 
recognizes only full-length GATA1, while the C-terminal antibody recognizes both GATA1 
isoforms (flGATA1 and GATA1s). (B) Loss of flGATA1 expression in the GATA1c.-21A>G 
patient’s bone marrow. Note that (i) flGATA1 is not expressed in all hematopoietic cells of a 
healthy individual, and (ii) GATA1s production is not affected by the GATA1c.-21A>G 
mutation. (C) Expression of N-terminal GATA1 domain (flGATA1; blue) is restricted to 
erythroblasts and megakaryocytes during human hematopoiesis. Appropriate hematopoietic 
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lineage markers (brown) were co-stained as shown. (D) GATA1s mutations cause a range of 
phenotypes from Diamond-Blackfan anemia (red) to multilineage hematopoietic dysplasia 
(blue). Novel mutation described in this work is marked with asterisk. The arrow indicates 
that the long-term risk of MDS in GATA1s patients presenting with pure RBC aplasia 
remains to be determined as one GATA1s patient initially diagnosed with DBA developed 
MDS later in childhood [12].
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